Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens

Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

(2021) Marta Rava et al.   AIDS

Reasons for Choice of Antiretroviral Regimens in HIV Patients Presenting Late for Initial Treatment in Europe

(2021) Gundolf Schuettfort et al.   AIDS PATIENT CARE AND STDS

Four Decades of HIV/AIDS — Much Accomplished, Much to Do

(2020) Anthony S. Fauci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

(2020) Chloe Orkin et al.   Lancet HIV

Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors

(2020) G Schuettfort et al.   HIV MEDICINE

Trends in practice: attitudes and challenges in the diagnosis, treatment and management of HIV infection in Australia

(2020) Don E. Smith et al.   INTERNAL MEDICINE JOURNAL

Adherence to HIV treatment regimens: systematic literature review and meta-analysis

(2019) Frederick Altice et al.   Patient Preference and Adherence

Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis

(2019) Sonya J. Snedecor et al.   BMC INFECTIOUS DISEASES

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

(2019)   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study

(2019) Barbara Rossetti et al.   ANTIVIRAL RESEARCH

Management of Advanced HIV Disease

(2019) Nathan A. Summers et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4

(2019) Cristina Mussini et al.   PLoS One

Advanced HIV: diagnosis, treatment, and prevention

(2019) Sandeep Prabhu et al.   Lancet HIV

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

(2018) Joseph J. Eron et al.   AIDS

Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs

(2018) et al.   CLINICAL INFECTIOUS DISEASES

Emergence of Polyfunctional Cytotoxic CD4+ T Cells in Mycobacterium avium Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients

(2018) Denise C Hsu et al.   CLINICAL INFECTIOUS DISEASES

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Aberrant Inflammasome Activation Characterizes Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome

(2016) Hong Yien Tan et al.   JOURNAL OF IMMUNOLOGY

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study

(2016) Kathleen Squires et al.   Lancet HIV

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Mycobacterial Antigen Driven Activation of CD14++CD16− Monocytes Is a Predictor of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome

(2014) Bruno B. Andrade et al.   PLoS Pathogens

The end of AIDS: HIV infection as a chronic disease

(2013) Steven G Deeks et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome

(2012) Y. D. Mahnke et al.   BLOOD

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Late presentation of HIV infection: a consensus definition

(2010) A Antinori et al.   HIV MEDICINE

The Economic Burden of Late Entry Into Medical Care for Patients With HIV Infection

(2010) John A. Fleishman et al.   MEDICAL CARE

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

(2009) Anthony M Mills et al.   AIDS

Antiretroviral therapy of late presenters with advanced HIV disease

(2008) M. Battegay et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY